磷酸氟达拉滨联合全身照射后供者外周血干细胞移植治疗骨髓增生异常综合征或骨髓增殖性肿瘤
该数据集来自 clinicaltrials.gov,聚焦于磷酸氟达拉滨联合全身照射后行供者外周血干细胞移植,用于治疗骨髓增生异常综合征或骨髓增殖性肿瘤患者

基本信息
资源简介
磷酸氟达拉滨联合全身照射后供者外周血干细胞移植治疗骨髓增生异常综合征或骨髓增殖性肿瘤
该数据集来自 clinicaltrials.gov,聚焦于磷酸氟达拉滨联合全身照射后行供者外周血干细胞移植,用于治疗骨髓增生异常综合征或骨髓增殖性肿瘤患者。覆盖病种包括非典型慢性髓系白血病、慢性粒单核细胞白血病、原发性骨髓增生异常综合征、原发性血小板增多症、骨髓增殖性肿瘤、阵发性睡眠性血红蛋白尿症及真性红细胞增多症等。主要目标为将第200天造血细胞移植失败率降至20%以下,次要目标涉及复发/进展率、无进展生存概率、供者植入动力学及移植相关并发症发生率。可用于移植预后预测与疗效评估(来源 clinicaltrials.gov)。
【数据内容】
源站描述(机器翻译,仅供参考):条件:非典型慢性髓系白血病,BCR-ABL1阴性,慢性粒单核细胞白血病,原发性骨髓增生异常综合征,原发性血小板增多症,骨髓增殖性肿瘤,阵发性睡眠性血红蛋白尿症,真性红细胞增多症,真性红细胞增多症,红细胞增多后骨髓纤维化期。主要目标:I. 将骨髓增生异常综合征-难治性贫血(RA)-(环形铁粒幼细胞[RS])/骨髓增殖性肿瘤(MPD)患者以及慢性粒单核细胞白血病(CMML)/难治性贫血伴原始细胞增多(RAEB)患者的第200天造血细胞移植(HCT)失败率降至<20%。次要目标:I. MPD或MDS-RA患者以及CMML或MDS-RAEB患者的复发/进展率。II. MPD或MDS-RA患者以及CMML或MDS-RAEB患者的无进展生存(PFS)概率。III. 供者植入动力学。IV. i的发生率
【主题与分类】
主题标签:Chronic Myelomonocytic Leukemia、de Novo Myelodysplastic Syndrome、Essential Thrombocythemia、Myeloproliferative Neoplasm、Paroxysmal Nocturnal Hemoglobinuria、Polycythemia Vera、Primary Myelofibrosis、Refractory Anemia、Refractory Anemia With Excess Blasts、Refractory Anemia With Ring Sideroblasts。本站分类:肿瘤/白血病。
【获取与许可】
源站页面:https://clinicaltrials.gov/study/NCT00397813
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取
源站:https://clinicaltrials.gov/study/NCT00397813
标准获取流程:
- 访问源站链接,注册/登录账号;
- 进入数据集详情页,按页面指引申请权限或直接下载;
- 部分平台提供 SDK,例如:
- OpenDataLab:
pip install openxlab后openxlab.dataset.get(...) - ModelScope:
pip install modelscope后modelscope download - 天池: 登录后页面提供直链下载
以源站「数据下载/使用文档」页面为准。
- OpenDataLab:
数据说明
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase. PRIMARY OBJECTIVES: I. Decrease the incidence of day-200 hematopoietic cell transplantation (HCT) failure to < 20% in patients with MDS-Refractory anemia (RA)-(ringed sideroblasts [RS])/MPD and in patients with chronic myelomonocytic leukemia (CMML)/refractory anemia with excess blasts (RAEB). SECONDARY OBJECTIVES: I. The rate of relapse/progression in patients with MPD or MDS-RA and those with CMML or MDS-RAEB. II. The probability of progression free survival (PFS) in patients with MPD or MDS-RA and those with CMML or MDS-RAEB. III. The kinetics of donor engraftment. IV. The incidence of infections. OUTLINE: This is a dose-escalation study of total body irradiation (TBI). NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -4 to -2 and undergo TBI on day 0. PERIPHERAL BLOOD STEM CELL (PBSC) TRANSPLANTATION: Patients undergo filgrastim (G-CSF)-mobilized PBSC infusion after TBI on day 0. IMMUNOSUPPRESSION: Matched Related Donor: Patients receive cyclosporine orally (PO) twice daily (BID) on days -3 to 56, followed by a taper until day 180. Patients also receive mycophenolate mofetil (MMF) PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27. Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96. After completion of study treatment, patients are followed periodically.
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




